Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1268 - Efficacy of tumor treating field therapy alone and in combination with doxorubicin in cellular model of breast cancer

Date

17 Dec 2016

Session

Poster lunch

Presenters

Nadia Gharaee

Citation

Annals of Oncology (2016) 27 (suppl_9): ix1-ix8. 10.1093/annonc/mdw573

Authors

N. Gharaee, M. Habibpour, H. Sepehri, L. Delphi

Author affiliations

  • Biology, Tehran university, 1417614418 - Tehran/IR
More

Resources

Abstract 1268

Background

Tumor treating fields (TTFs) are alternating fields with low intensity and intermediate frequency, that are used as a novel treatment for cancer therapy. TTFields lead to disruption in mitotic process and inhibit the proliferation of cancer cells. In the present study the effect of TTF therapy in cellular model of breast cancer is investigated. For this goal TTFields alone and in combination with doxorubicin as a chemical drug were examined.

Methods

MDA-MB-231 human breast cancer cells was exposed to TTFields for a duration of 30hours.TTFields also applied when cells were treated with doxorubicin in IC10 dose. The cells proliferation ratio was assessed after 72h.

Results

Treatment with tumor treating fields inhibits the proliferation of cancer cells significantly. The optimal frequency that caused the most inhibitory effect was determined to be 150kHz. Combination of TTF therapy with using of optimal frequency and treatment with doxorubicin in IC10 dose led to further decrease in proliferation, compared to TTF therapy alone. Moreover, the sensitivity to chemotherapeutic agent was increased by the aid of TTFields.

Conclusions

These findings demonstrated that TTFields contain efficiency to arrest cancer cells proliferation. These results also show that TTFields can support chemical drug efficiency. Our studies indicate that, using TTF co-administrated with doxorubicin can be used as an alternative strategy for cancer therapy in breast cancer cases to improve the effects of the drugs and increase the sensitivity of cancer cells.

Clinical trial indentification

Legal entity responsible for the study

Ministry of Science, Research and Technology Tehran University

Funding

Biology Department of Tehran University

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings